Want to see AU:ALC full AI Analyst Report?
Top Page
Alcidion Group Limited
(Sydney:ALC)
Select Model
Select Model
Rating:61Neutral
Price Target:
AU$0.11
▲(11.00% Upside)
Action:Reiterated
Date:08/20/26
The score is primarily supported by improving fundamentals and strong balance-sheet quality (very low leverage) with positive recent cash generation. This is materially offset by weak technical conditions (below key moving averages with negative MACD and very low RSI) and a high P/E valuation without a stated dividend yield.
Positive Factors
Very low leverage
Alcidion’s extremely low leverage reduces refinancing pressure and interest-related constraints, preserving financial flexibility. A conservatively financed balance sheet can support continued product investment, customer implementations, and strategic growth while improving resilience if healthcare spending becomes less predictable.
Negative Factors
Modest profitability
Although Alcidion is profitable again, its margins and return on equity remain modest. Limited profitability leaves less room to absorb implementation costs or invest aggressively in growth, and it means revenue expansion may not translate into proportionate earnings or cash generation without further operating improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Alcidion’s extremely low leverage reduces refinancing pressure and interest-related constraints, preserving financial flexibility. A conservatively financed balance sheet can support continued product investment, customer implementations, and strategic growth while improving resilience if healthcare spending becomes less predictable.
Read all positive factors
Alcidion Group Limited (ALC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$141.73M
Dividend YieldN/A
Average Volume (3M)1.34M
Price to Earnings (P/E)61.8
Beta (1Y)0.95
Revenue Growth26.61%
EPS Growth41.67%
CountryAU
Employees141
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,349,805,200
10 Day Avg. Volume1,151,474
30 Day Avg. Volume1,335,398
Financial Highlights & Ratios
PEG Ratio1.48
Price to Book (P/B)1.55
Price to Sales (P/S)2.73
P/FCF Ratio21.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside45.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$53.97M
Alcidion Group Limited Business Overview & Revenue Model
Company Description
Alcidion Group Limited operates as a healthcare technology firm, specializing in the creation and licensing of software products across Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a consolidated platfor...
How the Company Makes Money
Alcidion makes money primarily by selling and supporting its healthcare software to hospital and healthcare customers. Key revenue streams include: (1) recurring software revenue from licensing/subscriptions and ongoing support/maintenance for its...
Alcidion Group Limited Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
88
Very Positive
Cash Flow
70
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 51.64M | 40.79M | 37.06M | 40.40M | 34.35M |
| Gross Profit | 9.16M | 35.99M | 31.92M | 1.25M | 3.29M |
| EBITDA | 2.55M | 1.94M | -4.50M | -1.43M | -1.58M |
| Net Income | 2.29M | 1.65M | -8.42M | -3.62M | -4.41M |
Balance Sheet | |||||
| Total Assets | 121.88M | 115.63M | 114.46M | 120.68M | 128.35M |
| Cash, Cash Equivalents and Short-Term Investments | 20.64M | 17.70M | 11.80M | 14.64M | 17.34M |
| Total Debt | 814.00K | 1.41M | 1.70M | 2.15M | 2.48M |
| Total Liabilities | 31.01M | 27.82M | 27.52M | 30.52M | 34.40M |
| Stockholders Equity | 90.87M | 87.80M | 86.94M | 90.17M | 93.95M |
Cash Flow | |||||
| Free Cash Flow | 6.62M | 5.64M | -7.18M | -285.00K | 685.00K |
| Operating Cash Flow | 6.85M | 5.76M | -7.13M | 169.00K | 996.00K |
| Investing Cash Flow | -1.70M | -125.00K | -53.00K | -3.14M | -59.74M |
| Financing Cash Flow | -800.00K | -764.00K | 4.34M | -616.00K | 51.33M |
Alcidion Group Limited Technical Analysis
Positive
0.10
Price Trends
0.09
Positive
0.10
Positive
0.10
Negative
Market Momentum
<0.01
Negative
58.35
Neutral
99.80
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALC, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.09, and below the 200-day MA of 0.10, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.35 is Neutral, neither overbought nor oversold. The STOCH value of 99.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ALC.
Alcidion Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$18.17B | 68.48 | 63.19% | 0.40% | 22.87% | 130.30% | |
61 Neutral | AU$141.73M | 61.76 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$163.64M | -9.45 | -203.69% | ― | -1.53% | 28.29% | |
49 Neutral | AU$35.44M | -1.91 | -58.13% | ― | 2.08% | -195.31% | |
47 Neutral | AU$65.80M | -7.37 | -24.29% | ― | -17.35% | -47.29% | |
47 Neutral | AU$682.85M | -24.02 | -30.04% | ― | <0.01% | 2.08% |
* Healthcare Sector Average
AU:ALC
Alcidion Group Limited
0.11
0.02
16.67%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.20
-0.04
-17.02%
AU:PME
Pro Medicus Limited
173.95
-124.75
-41.76%
AU:M7T
Mach7 Technologies
0.28
-0.03
-11.11%
AU:BMT
Beamtree Holdings Ltd
0.12
-0.11
-47.83%
AU:AYA
Artrya Limited
4.18
2.00
91.74%
Alcidion Group Limited Corporate Events
Alcidion Seeks ASX Quotation for 6.2 Million New Shares
Sep 3, 2026
Alcidion Group Limited has applied for quotation on the ASX of 6,246,397 new fully paid ordinary shares, to be issued on 4 September 2026. The additional securities arise from the exercise or conversion of existing options or other convertible ins...
ASX drops quarterly cash flow reporting for financially strengthened Alcidion
Sep 3, 2026
Healthcare technology provider Alcidion Group Limited has secured relief from the Australian Securities Exchange’s requirement to lodge quarterly cash flow reports, reflecting a significantly strengthened balance sheet and operating performa...
Alcidion Director Andrew Way Increases Shareholding via On-Market Trade
Aug 27, 2026
Alcidion Group Limited has reported a change in the shareholding of director Andrew Way, in line with ASX disclosure rules and the Corporations Act. The company remains focused on compliance with market regulations that govern director interests a...
Alcidion Director Andrew Way Boosts Shareholding in On-Market Trades
Aug 27, 2026
Alcidion Group Limited has disclosed a change in director Andrew Way’s holdings, with the director purchasing additional fully paid ordinary shares in two on-market trades. The acquisitions, executed at $0.093 per share, increased Way’...
Alcidion Details 2026 Governance and Diversity Framework
Aug 18, 2026
Alcidion Group Limited has released its 2026 Corporate Governance Statement, outlining how its Board oversees strategy, risk and management while aiming to protect shareholder interests and consider broader stakeholders. The statement details the ...
Alcidion Files ASX Corporate Governance Statement for 2026
Aug 18, 2026
Alcidion Group Limited has lodged its annual corporate governance disclosures with the ASX for the year ended 30 June 2026, including an Appendix 4G and a governance statement made available through its website. The governance statement, approved ...
Alcidion Releases FY26 Results Presentation with Extensive Investor Disclaimers
Aug 18, 2026
Alcidion Group Limited has released its FY26 results presentation, outlining financial and operational information for the period in Australian dollars and highlighting the use of non‑IFRS metrics such as underlying NPAT and EBITDA. The docu...
Alcidion posts record FY26 profit as Kyra acquisition and NHS deals fuel growth
Aug 18, 2026
Alcidion reported FY26 revenue of $51.6 million, up 27% year on year, with 63% generated in the U.K. and 37% in ANZ, and lifted Annual Recurring Revenue to $38.3 million, a 34% increase. Underlying EBITDA rose 34% to $6.8 million and NPAT climbed ...
Alcidion to Present FY26 Results in Investor Webcast
Aug 12, 2026
Alcidion Group Limited, a healthcare IT specialist focused on clinical decision support and interoperability, has built its offering around the Miya Precision platform to help hospitals and healthcare organisations improve patient outcomes. The co...
Alcidion Issues 1.9 Million Unquoted Performance Rights Under Incentive Scheme
Aug 11, 2026
Alcidion Group Limited has notified the market of the issue of 1,912,175 unquoted performance rights under its employee incentive scheme. The new securities, which are not intended to be quoted on the ASX, were issued on 12 August 2026, reflecting...
Alcidion Delivers Record Cashflow, Secures Major EPR Deals and Expands Patient Flow Footprint
Jul 22, 2026
Alcidion reported a record Q4 FY26 with positive operating cashflow of $7.7 million and quarterly cash receipts of $24.6 million, contributing to full-year operating cashflow of $6.8 million and unaudited revenue of about $51.6 million. The compan...
Alcidion targets Asian investors with Singapore and Hong Kong roadshow
Jun 28, 2026
Alcidion Group Limited is a healthcare technology provider focused on digital solutions that streamline clinical workflows, enhance interoperability and support real-time clinical decision-making for hospitals and healthcare organisations. Its cor...
Alcidion Reconfirms FY26 Outlook and Closes Telstra Health Kyra Acquisition
Jun 28, 2026
Alcidion has reaffirmed its full-year FY26 guidance, expecting revenue to exceed $50 million, EBITDA to surpass $5 million and operating cash flow to remain broadly in line with the prior year, underpinned by strong financial performance and long-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.